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Dr Harold L. Lazar (Boston, Mass). In their study, Dr Halkos and
colleagues found that an elevated preoperative HbA1c level was as-
sociated with a significant increase in mortality and morbidity. This
is not surprising because patients with an elevated HbA1c had
a higher incidence of preoperative renal failure, strokes, peripheral
vascular disease, and diffuse coronary artery disease, which required
more grafts. All of these factors are independently known to be pre-
dictive of adverse outcomes after bypass surgery.
My first question is whether an elevated HbA1c is a marker of
advanced diabetic end-organ disease or does it really represent
poor intraoperative glycemic control? Did you actually measure
the perioperative glucose values between the high and low HbA1c
groups to see whether or not your protocols actually achieved tight
glycemic control in the elevated HbA1c group, and did the patients
with elevated HbA1c levels who had lower perioperative glucose
values have decreased morbidity and mortality?
DrHalkos.Letmefirst start by addressing the question regarding
tight intraoperative glycemic control. We did not collect those data
because they were not accessible to us regarding the blood glucose
levels in the operating room and intensive care unit setting. However,
all of our patients undergoing primary electiveCABGaremaintained
in the same fashion with regard to the regimen in which their blood
glucose is controlled both in the operating room and in the intensive
care unit, as well as how they are transitioned on the floor.
Dr Lazar. I think that may be important data because we have
found that it is more difficult to achieve tighter glycemic control
in patients with elevated HbA1c even though there is a set protocol.
I may actually answer your first clinical implication as to whether or
not these patients can be delayed. Perhaps these patients may have to
have more vigorous intraoperative control of their glucose levels.
My second question is, were the adverse effects of an elevated
HbA1c related to the type of diabetes? In other words, did insulin-
dependent diabetic patients have worse outcomes compared with
patients treated with oral agents or diet alone?racic and Cardiovascular Surgery c Volume 136, Number 3 639
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A
CDDr Halkos. Let me answer that with regard to a previous ques-
tion that you asked regarding patients with elevated HbA1c: Are the
intraoperative and perioperative glucose levels or the comorbidities
associated with poorly controlled diabetes? We believe that it may
very well be the comorbidities associated with poorly controlled di-
abetes, which is reflected by an elevated HbA1c. With regard to the
last question, rephrase that last part for me.
Dr Lazar. Did insulin diabetic patients have worse outcomes
than those with oral agents or diet alone?
Dr Halkos. We did not look into the subgroupings of how dia-
betes was controlled in patients with regard to their method of con-
trol. In our study, approximately 20% of patients were receiving
insulin therapy, and then 50% were receiving oral hypoglycemic
medications or a combination thereof. So part of the reason for
not looking at the data in that fashion was the combination thereof
was not well defined in our database.
Dr Lazar. Patients in the elevated HbA1c group had signifi-
cantly higher mortality. What were the differences in the cause of
death between the groups? Were the patients with elevated HbA1c
more likely to die of cardiac causes or was it more related to their
increased incidence of renal fairly, strokes, and peripheral vascular
disease?
Dr Halkos. With regard to the cause of death, we really didn’t
look into the cause with regard to their cause of mortality other
than report the associated morbidities.
Dr Lazar. In your study, 70% of patients underwent off-pump
surgery, yet patients with an elevated HbA1c were more likely to un-
dergo on-pump surgery. What was the crossover rate from the off-
pump to the on-pump groups in this study, and were the patients
with an elevated HbA1c who crossed over more likely to have an640 The Journal of Thoracic and Cardiovascular Surgery c Sepadverse outcome? I must say these data were derived from the arti-
cle, which you were kind enough to send to me in advance.
Dr Halkos. Yes, sir. I don’t know the exact crossover rate, but I
know that during the period of the study it was very low, with a 2%
crossover. Patients were categorized according to whether they un-
derwent on- or off-pump surgery according to the ultimate proce-
dure that was used. So that is a piece of data that can be
misleading. We believe that even though slightly more patients un-
derwent on-pump surgery in the higher A1c subgroup, that was only
approximately 4% to 5% higher than the A1c group (,7%).
Dr Lazar. Recent studies have shown that patients receiving an-
giotensin-converting enzyme inhibitors, beta-blockers, and statins
in the perioperative period have decreased morbidity and mortality.
Can you tell us what percentage of patients in the study received
these medications and was there a difference in the use of these med-
ications between the HbA1c groups?
Dr Halkos. Again, almost all of our patients are managed in the
same way: They receive aspirin preoperatively, angiotensin-con-
verting enzyme inhibitors are discontinued preoperatively in almost
all patients, and they receive beta-blocker therapy.
Dr Lazar. One final question, again from the article. Your data
implied that elevated HbA1c levels were actually protective from
developing atrial fibrillation. In other words, people with elevated
HbA1c actually had a lower incidence of atrial fibrillation. Can
you explain that and give us an idea of what the mechanism was?
Dr Halkos.We reported all of these outcomes, and in this study,
which was not presented in the slides, there was a 30% lower inci-
dence of atrial fibrillation in patients with an elevated A1c, but this
was statistically significant, and we do not have a mechanism to
explain why that difference existed.tember 2008
